$20.81
+0.59 (+2.92%)
Open$20.00
Previous Close$20.22
Day High$21.24
Day Low$19.55
52W High$29.28
52W Low$5.55
Volume—
Avg Volume256.6K
Market Cap706.09M
P/E Ratio—
EPS$-1.20
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+31.7% upside
Current
$20.81
$20.81
Target
$27.40
$27.40
$23.46
$27.40 avg
$40.51
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 66.09M | 69.56M | 73.83M |
| Net Income | 7.65M | 9.76M | 11.38M |
| Profit Margin | 11.6% | 14.0% | 15.4% |
| EBITDA | 12.79M | 14.57M | 15.15M |
| Free Cash Flow | 6.98M | 8.54M | 10.02M |
| Rev Growth | +12.3% | +24.1% | -0.1% |
| Debt/Equity | 0.76 | 0.65 | 0.75 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.29 | -1.12% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $423.64 | +1.32% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $151.28 | -0.61% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.73 | -0.18% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $750.51 | -0.23% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $254.07 | -0.51% | 41.4 | 33.44B |